Patients who have non-Hodgkin's lymphoma or Hodgkin lymphoma most often present for
medical attention because of signs or symptoms referable to enlarged lymph nodes or
other disease-related symptoms (such as fevers, night sweats or fatigue). Less often,
enlarged lymph nodes or splenomegaly may be incidental findings during evaluation
for other medical issues. Determination of the extent of disease and accurate assessment
of responses are necessary for appropriate management. Newer technologies have improved
the ability to evaluate patients and to conduct clinical trials, leading to more effective
therapies. This article addresses the advances in staging and evaluation of patients
who have lymphoma, specifically examining the use of positron emission tomography.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The epidemiology of non-Hodgkin's lymphoma.Oncogene. 2004; 23: 6524-6534
- Quantification of the impact of known risk factors on time trends in non-Hodgkin's lymphoma incidence.Cancer Res. 1992; 52: 5566s-5569s
- Time trends of non-Hodgkin's lymphoma: are they real? What do they mean?.Cancer Res. 1992; 52: 5443s-5446s
- Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998.J Natl Cancer Inst. 2002; 94: 1204-1210
- The role of environmental factors in the etiology of lymphoma.Cancer Invest. 2008; 26: 306-316
- The emerging concept of antigen-driven lymphomas: epidemiology and treatment implications.Curr Opin Oncol. 2006; 18: 417-424
- The role of molecular studies in lymphoma diagnosis: a review.Pathology. 2004; 36: 19-44
- The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.N Engl J Med. 2002; 346: 1937-1947
- Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response.Blood. 2005; 105: 1851-1861
- Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.Blood. 2004; 103: 275-282
- Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes.N Engl J Med. 2004; 350: 1828-1837
- Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.N Engl J Med. 1998; 339: 21-26
- CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: update of the Southwest Oncology Group (SWOG) randomized trial.Blood. 2001; 98: 724a-725a
- Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484.J Clin Oncol. 2004; 22: 3032-3038
- Gene expression differences between low and high stage diffuse large B cell lymphoma.Blood. 2006; 108: 196a
- ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.N Engl J Med. 2005; 352: 1197-1205
- CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte.J Clin Oncol. 2007; 25: 787-792
Persky DO, Unger JM, Spier CM, et al. Effect of adding rituximab to three cycles of CHOP plus involved-field radiotherapy for patients with limited stage aggressive B-cell lymphoma. J Clin Oncol, in press.
- CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.Lancet Oncol. 2006; 7: 379-391
- Limited-stage diffuse large B cell lymphoma patients with a negative PET scan following three cycles of R-CHOP can be effectively treated with abbreviated chemoimmunotherapy alone.Blood. 2007; 110: 242a
- Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.N Engl J Med. 1993; 328: 1002-1006
- CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.N Engl J Med. 2002; 346: 235-242
- Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.J Clin Oncol. 2005; 23: 4117-4126
- Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.J Clin Oncol. 2006; 24: 3121-3127
- Maintenance rituximab compared to observation after R-CHOP or CHOP in older patients with diffuse large B-cell lymphoma.J Clin Oncol. 2007; 25: 443s
- 2-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.Blood. Feb 24 2004;
- 2-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.Blood. Mar 11 2004;
- Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).Lancet Oncol. 2008; 9: 105-116
- Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.N Engl J Med. 2004; 350: 1287-1295
- Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma.Blood. 2003; 101: 2756-2761
- The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.Blood. 2003; 102: 3871-3879
- Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience.Ann Oncol. 2006; 17: 123-130
- Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group.J Clin Oncol. 2003; 21: 20-27
- Lymphomatoid granulomatosis: pathogenesis, pathology and clinical implications.Cancer Surv. 1997; 30: 233-248
- Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b.Blood. 1996; 87: 4531-4537
- Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.J Clin Oncol. 2006; 24: 4867-4874
- Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.Nat Med. 2002; 8: 68-74
- Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.J Clin Oncol. 2007; 25: 1741-1746
- Preliminary results from a phase II study of lenalidomide monotherapy in relapsed/refractory aggressive non-Hodgkin's lymphoma.Blood. 2006; 106: 531
- Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation.Blood. 2007; 110: 54-58
- Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.Blood. 2004; 103: 3684-3688
- Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.N Engl J Med. 1995; 333: 1540-1545
- Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.Blood. 1998; 92: 1927-1932
Article info
Footnotes
Dr. Friedberg is partially funded by a Scholar in Clinical Research award from the Leukemia & Lymphoma Society.
Identification
Copyright
© 2008 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
